Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. / Schuster, H.; Fagerberg, B.; Edwards, S.; Halmos, T.; Lopatynski, J.; Stender, S.; Birketvedt, G.S.; Tonstad, S.; Gause-Nilsson, I.; Halldorsdottir, S.; Ohman, K.P.

I: Atherosclerosis, Bind 197, Nr. 1, 2008, s. 355-362.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Schuster, H, Fagerberg, B, Edwards, S, Halmos, T, Lopatynski, J, Stender, S, Birketvedt, GS, Tonstad, S, Gause-Nilsson, I, Halldorsdottir, S & Ohman, KP 2008, 'Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance', Atherosclerosis, bind 197, nr. 1, s. 355-362.

APA

Schuster, H., Fagerberg, B., Edwards, S., Halmos, T., Lopatynski, J., Stender, S., Birketvedt, G. S., Tonstad, S., Gause-Nilsson, I., Halldorsdottir, S., & Ohman, K. P. (2008). Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis, 197(1), 355-362.

Vancouver

Schuster H, Fagerberg B, Edwards S, Halmos T, Lopatynski J, Stender S o.a. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis. 2008;197(1):355-362.

Author

Schuster, H. ; Fagerberg, B. ; Edwards, S. ; Halmos, T. ; Lopatynski, J. ; Stender, S. ; Birketvedt, G.S. ; Tonstad, S. ; Gause-Nilsson, I. ; Halldorsdottir, S. ; Ohman, K.P. / Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. I: Atherosclerosis. 2008 ; Bind 197, Nr. 1. s. 355-362.

Bibtex

@article{fb9061e005b011deb05e000ea68e967b,
title = "Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance",
abstract = "Aim: To determine the effects of the peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar on serum levels of apolipoprotein (apo) A-I, apoB, and apoCIII in non-diabetic insulin-resistant subjects. Methods: This randomized, double-blind, multicentre, placebo-controlled trial examined the effect of tesaglitazar (0.1, 0.25, 0.5, and 1 mg) once daily for 12 weeks on apolipoprotein levels in 390 abdominally obese subjects with hypertriglyceridaemia. Results: Tesaglitazar dose-dependently increased serum concentrations of apoA-I (p < 0.009) and decreased concentrations of apoB (p < 0.0001), the apoB/apoA-I ratio (p < 0.0001), and apoCIII (p < 0.0001). Similar improvements were observed in all subgroups of subjects, where individuals were grouped according to age, gender, baseline body mass index, serum triglycerides and high-density lipoprotein cholesterol levels. Low-density lipoprotein particle concentrations were also dose-dependently reduced by tesaglitazar (P < 0.0001). Conclusion: Although tesaglitazar is no longer in clinical development, these data indicate that dual PPAR alpha/gamma agonism may be a useful pharmacological approach to improve the atherogenic dyslipidaemia associated with insulin resistance. (C) 2007 Elsevier Ireland Ltd. All rights reserved Udgivelsesdato: 2008/3",
author = "H. Schuster and B. Fagerberg and S. Edwards and T. Halmos and J. Lopatynski and S. Stender and G.S. Birketvedt and S. Tonstad and I. Gause-Nilsson and S. Halldorsdottir and K.P. Ohman",
note = "Times Cited: 1ArticleEnglishSchuster, HInfogen, Xantener Str 10, D-10707 Berlin, GermanyCited References Count: 32282LSELSEVIER IRELAND LTDELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDCLARE",
year = "2008",
language = "English",
volume = "197",
pages = "355--362",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance

AU - Schuster, H.

AU - Fagerberg, B.

AU - Edwards, S.

AU - Halmos, T.

AU - Lopatynski, J.

AU - Stender, S.

AU - Birketvedt, G.S.

AU - Tonstad, S.

AU - Gause-Nilsson, I.

AU - Halldorsdottir, S.

AU - Ohman, K.P.

N1 - Times Cited: 1ArticleEnglishSchuster, HInfogen, Xantener Str 10, D-10707 Berlin, GermanyCited References Count: 32282LSELSEVIER IRELAND LTDELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELANDCLARE

PY - 2008

Y1 - 2008

N2 - Aim: To determine the effects of the peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar on serum levels of apolipoprotein (apo) A-I, apoB, and apoCIII in non-diabetic insulin-resistant subjects. Methods: This randomized, double-blind, multicentre, placebo-controlled trial examined the effect of tesaglitazar (0.1, 0.25, 0.5, and 1 mg) once daily for 12 weeks on apolipoprotein levels in 390 abdominally obese subjects with hypertriglyceridaemia. Results: Tesaglitazar dose-dependently increased serum concentrations of apoA-I (p < 0.009) and decreased concentrations of apoB (p < 0.0001), the apoB/apoA-I ratio (p < 0.0001), and apoCIII (p < 0.0001). Similar improvements were observed in all subgroups of subjects, where individuals were grouped according to age, gender, baseline body mass index, serum triglycerides and high-density lipoprotein cholesterol levels. Low-density lipoprotein particle concentrations were also dose-dependently reduced by tesaglitazar (P < 0.0001). Conclusion: Although tesaglitazar is no longer in clinical development, these data indicate that dual PPAR alpha/gamma agonism may be a useful pharmacological approach to improve the atherogenic dyslipidaemia associated with insulin resistance. (C) 2007 Elsevier Ireland Ltd. All rights reserved Udgivelsesdato: 2008/3

AB - Aim: To determine the effects of the peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist tesaglitazar on serum levels of apolipoprotein (apo) A-I, apoB, and apoCIII in non-diabetic insulin-resistant subjects. Methods: This randomized, double-blind, multicentre, placebo-controlled trial examined the effect of tesaglitazar (0.1, 0.25, 0.5, and 1 mg) once daily for 12 weeks on apolipoprotein levels in 390 abdominally obese subjects with hypertriglyceridaemia. Results: Tesaglitazar dose-dependently increased serum concentrations of apoA-I (p < 0.009) and decreased concentrations of apoB (p < 0.0001), the apoB/apoA-I ratio (p < 0.0001), and apoCIII (p < 0.0001). Similar improvements were observed in all subgroups of subjects, where individuals were grouped according to age, gender, baseline body mass index, serum triglycerides and high-density lipoprotein cholesterol levels. Low-density lipoprotein particle concentrations were also dose-dependently reduced by tesaglitazar (P < 0.0001). Conclusion: Although tesaglitazar is no longer in clinical development, these data indicate that dual PPAR alpha/gamma agonism may be a useful pharmacological approach to improve the atherogenic dyslipidaemia associated with insulin resistance. (C) 2007 Elsevier Ireland Ltd. All rights reserved Udgivelsesdato: 2008/3

M3 - Journal article

VL - 197

SP - 355

EP - 362

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -

ID: 10914236